ALS Phase 3 Study TRO19622

What is ALS Phase 3 Study TRO19622?

CATEGORY:

NCT01285583 is an open-label safety extension study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole. The drug TRO19622 is also known as olesoxime. Other study names are TRO19622 CL E Q 1425-1.

Save up to 80% off your prescriptions!

How do members experience ALS Phase 3 Study TRO19622?

Top 5 reported purposes & perceived effectiveness

Purpose Patients Evaluations Perceived Effectiveness
Participate in clinical trial 3 3

Side effect severity

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 0
None 4

Member evaluations

Madryn

evaluated on Dec 28, 2011

  • Perceived effectiveness for Participate in clinical trial: None
  • Side effects: None

cinéphile 94

evaluated on Dec 14, 2011

  • Perceived effectiveness for Participate in clinical trial: None
  • Side effects: None
Learn more about our community’s experience with ALS Phase 3 Study TRO19622

What are people saying about ALS Phase 3 Study TRO19622?

5

5

members have reported taking ALS Phase 3 Study TRO19622

Join the conversation and connect with people who have taken ALS Phase 3 Study TRO19622
Last updated:

Save up to 80% off your prescriptions!